Review article: Helicobacter pylori and reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 3, 2003, Pages 297-305

  Sharma, P ^a,c   Vakil, N ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAGA PROTEIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; DEVELOPED COUNTRY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ERADICATION THERAPY; ESOPHAGUS CARCINOMA; ESOPHAGUS MOTILITY; ESOPHAGUS PH; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOWER ESOPHAGUS SPHINCTER; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RELAPSE; REVIEW; STOMACH ACID SECRETION; SYMPTOM;

ADENOCARCINOMA; ANTIGENS, BACTERIAL; ATROPHY; BACTERIAL PROTEINS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYDROGEN-ION CONCENTRATION; RECURRENCE; STOMACH;

EID: 0037328025     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01428.x     Document Type: Review

References (58)

1. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113: 1983-91.
2. Blaser MJ. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-30.
3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
4. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-6.
5. El-Omar EM, Penman ID, Ardill JE, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1991; 109: 681-91.
6. Bercik P, Verdu E, Armstrong D, et al. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000; 95: 947-55.
7. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin N Am 2000; 29: 559-78.
8. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
9. Lord RV, Frommer DJ, Inder S, et al. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma. Aust NZ Surg 2000; 70: 26-33.
10. Hackelsberger A, Schultze V, Gunther T, et al. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Eur J Gastroenterol Hepatol 1998; 10: 465-8.
11. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997; 42: 103-5.
12. Wu JC, Sung JJ, Ng EK, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 1999; 94: 1790-4.
13. Varanasi RV, Fantry GT, Wilson KT. Decreased prevalence of H. pylori infection in gastroesophageal reflux disease. Helicobacter 1998; 3: 188-94.
14. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 1: 330-4.
15. O'Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease - clinical implications and management. Aliment Pharmacol Ther 1999; 13: 117-27.
16. Yamaji Y, Mitsushima T, Ikuma H, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: analysis of 5732 Japanese subjects. Gut 2001; 49: 335-40.
17. Watanabe Y, Fujjiwara Y, Shiba M, et al. Prevalence of gastroesophageal reflux disease in the Japanese population. Gastroenterology 2002; 122: A573(Abstract).
18. Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori. Gut 1993; 34(7): 888-92.
19. el-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C, McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109(3): 681-91.
20. Gutierrez O, Melo M, Segura AM, Angel A, Genta RM, Graham DY. Cure of Helicobacter pylori infection improves gastric acid secretion in patients with corpus gastritis. Scand J Gastroenterol 1997; 32(7): 664-8.
21. Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus - evaluation of 24 hour pH monitoring. Gut 1999; 13: 155-62.
22. Feldman M, Cryer B, Sammer D, Lee E, Spechler SJ. Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. Am J Physiol 1999; 277(6 Part 1): G1159-64.
23. Tefera S, Hatlebakk JG, Berstad A. The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. Aliment Pharmacol Ther 1999; 13: 915-20.
24. Manifold DK, Anggiansah A, Rowe I, Sanderson JD, Chinyama CN, Owen WJ. Gastro-esophageal reflux and duodenogastric reflux before and after eradication in Helicobacter pylori gastritis. Eur J Gastroenterol Hepatol 2001; 13(5): 535-9.
25. Wu JC, Lai AC, Wong SK, Chan FK, Leung WK, Sung JJ. Dysfunction of oesophageal motility in Helicobacter pylori-infected patients with reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 1913-9.
26. Wu JC, Chan FK, Wong SK, Lee YT, Leung WK, Sung JJ. Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. Aliment Pharmacol Ther 2002; 16: 545-52.
27. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
28. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-esophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
29. McColl K, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of ulcer disease. Am J Gastroenterol 2000; 95: 101-5.
30. Fallone C, Barkun A, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? Am J Gastroenterol 2000; 95: 914-20.
31. Hamada H, Haruma K, Mihara M, et al. High incidence of reflux esophagitis after eradication therapy for Helicobacter pylori; impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14: 729-35.
32. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 728-32.
33. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
34. Carlsson R, Bate C, Dent J, et al. Does H. pylori infection influence the response to treatment with acid inhibition in patients with GERD. Scand J Gastroenterol 1997; 32(Suppl. 224): F70.
35. Vakil N, Kahrilas P, Magner D, Skammer W, Levine J. Does baseline H. pylori status impact erosive esophagitis healing rates? Am J Gastroenterol 2000; 95: 2438.
36. Vakil N, Zuckerman S, Levine J. H. pylori infection and the severity of esophagitis and healing with lansoprazole and esomeprazole. Gastroenterology 2002; 122: A199(Abstract).
37. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 884-7.
38. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
39. Schwizer W, Thurmshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-esophageal reflux disease: a randomized controlled trial. Lancet 2001; 357: 1738-42.
40. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
41. Eissele R, Brunner G, Simon B, et al. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
42. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety and influence on gastric mucosa. Gastroenterology 2000; 118: 661-9.
43. Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 319-26.
44. Malfertheiner P, Megraud F, O'Morain C. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8-13.
45. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology (Suppl) 2000; 118: S2-S8.
46. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3.
47. Sharma P. Recent advances in Barrett's esophagus: short segment Barrett's esophagus and cardia intestinal metaplasia. Semin Gastrointest Dis 1999; 1C: 93-102.
48. Weston AP, Badr AS, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus. Barrett's dysplasia and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95: 387-94.
49. Kuipers EJ, Perez-Perez GI, Meuwissen SG, et al. Helicobacter pylori and atrophic gastritis: importance of the cag A status. J Natl Cancer Inst 1995; 87: 1777-80.
50. Peek RM, Miller GG, Perez-Perez GI, et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest 1995; 71: 760-70.
51. Van Doorn LJ, Figueiredo C, Sanna R, et al. Clinical relevance of cagA, vacA, and iceA status of Helicobacter pylori. Gastroenterology 1998; 115: 58-66.
52. Farthing MJ, Fitzgerald R, Zhang ZW. Acid, Helicobacter and immunity: a new paradigm for oesophagogastric cancer. J Physiol 2001; 95: 423-7.
53. Arents NL, vanZwet AA, Thijs JC, et al. The importance of vacA, cagA, and iceA genotypes of Helicobacter pylori infection in peptic ulcer disease and gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 2603-8.
54. Warburton-Timms VJ, Charlett A, Valori RM, et al. The significance of cagA+ Helicobacter pylori in reflux oesophagitis. Gut 2001; 49: 341-6.
55. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
56. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cag A+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-90.
57. Sharma VK, Howden CW. Decreased prevalence of H. pylori and cagA+ H. pylori in GERD and Barrett's esophagus (BE) with or without dysplasia or adenocarcinoma (D/AC): a meta-analysis. Gastroenterology 2002; 122: A291(Abstract).
58. Sharma P. Helicobacter pylori: a debated factor in gastroesophageal reflux disease. Digestive Dis 2001; 19: 129-35.